|
1
|
Adams J and Kauffman M: Development of the
proteasome inhibitor Velcade (Bortezomib). Cancer Invest.
22:304–311. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kisselev AF and Goldberg AL: Proteasome
inhibitors: From research tools to drug candidates. Chem Biol.
8:739–758. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Richardson PG, Barlogie B, Berenson J,
Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina
M, Alexanian R, et al: A phase 2 study of bortezomib in relapsed,
refractory myeloma. N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ludwig H, Sonneveld P, Davies F, Bladé J,
Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M,
Dimopoulos M, et al: European perspective on multiple myeloma
treatment strategies in 2014. Oncologist. 19:829–844. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Argyriou AA, Iconomou G and Kalofonos HP:
Bortezomib-induced peripheral neuropathy in multiple myeloma: A
comprehensive review of the literature. Blood. 112:1593–1599. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dispenzieri A, Jacobus S, Vesole DH,
Callandar N, Fonseca R and Greipp PR: Primary therapy with single
agent bortezomib as induction, maintenance and re-induction in
patients with high-risk myeloma: Results of the ECOG E2A02 trial.
Leukemia. 24:1406–1411. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Richardson PG, Xie W, Mitsiades C,
Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter
DJ, Wen PY, et al: Single-agent bortezomib in previously untreated
multiple myeloma: Efficacy, characterization of peripheral
neuropathy, and molecular correlations with response and
neuropathy. J Clin Oncol. 27:3518–3525. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen Z, Shi T, Zhang L, Zhu P, Deng M,
Huang C, Hu T, Jiang L and Li J: Mammalian drug efflux transporters
of the ATP binding cassette (ABC) family in multidrug resistance: A
review of the past decade. Cancer Lett. 370:153–164. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Clemens J, Seckinger A, Hose D, Theile D,
Longo M, Haefeli WE, Burhenne J and Weiss J: Cellular uptake
kinetics of bortezomib in relation to efficacy in myeloma cells and
the influence of drug transporters. Cancer Chemother Pharmacol.
75:281–291. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Siegel DS, Martin T, Wang M, Vij R,
Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M,
et al: A phase 2 study of single-agent carfilzomib (PX-171-003-A1)
in patients with relapsed and refractory multiple myeloma. Blood.
120:2817–2825. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Demo SD, Kirk CJ, Aujay MA, Buchholz TJ,
Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, et al:
Antitumor activity of PR-171, a novel irreversible inhibitor of the
proteasome. Cancer Res. 67:6383–6391. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuhn DJ, Chen Q, Voorhees PM, Strader JS,
Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan
AA, et al: Potent activity of carfilzomib, a novel, irreversible
inhibitor of the ubiquitin-proteasome pathway, against preclinical
models of multiple myeloma. Blood. 110:3281–3290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gentile M, Offidani M, Vigna E, Corvatta
L, Recchia AG, Morabito L, Morabito F and Gentilli S: Ixazomib for
the treatment of multiple myeloma. Expert Opin Investig Drugs.
24:1287–1298. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ocio EM, Mitsiades CS, Orlowski RZ and
Anderson KC: Future agents and treatment directions in multiple
myeloma. Expert Rev Hematol. 7:127–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Teicher BA and Tomaszewski JE: Proteasome
inhibitors. Biochem Pharmacol. 96:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Palumbo A, Bringhen S, Rossi D, Cavalli M,
Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli
T, et al: Bortezomib-melphalan-prednisone-thalidomide followed by
maintenance with bortezomib-thalidomide compared with
bortezomib-melphalan-prednisone for initial treatment of multiple
myeloma: A randomized controlled trial. J Clin Oncol. 28:5101–5109.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mai EK, Bertsch U, Dürig J, Kunz C, Haenel
M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, et al:
Phase III trial of bortezomib, cyclophosphamide and dexamethasone
(VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in
newly diagnosed myeloma. Leukemia. 29:1721–1729. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aras B and Yerlikaya A: Bortezomib and
etoposide combinations exert synergistic effects on the human
prostate cancer cell line PC-3. Oncol Lett. 11:3179–3184.
2016.PubMed/NCBI
|
|
20
|
Yerlikaya A, Erdoğan E, Okur E, Yerlikaya
Ş and Savran B: A novel combination treatment for breast cancer
cells involving BAPTA-AM and proteasome inhibitor bortezomib. Oncol
Lett. 12:323–330. 2016.PubMed/NCBI
|
|
21
|
Müller F and Fromm MF:
Transporter-mediated drug-drug interactions. Pharmacogenomics.
12:1017–1037. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weiss J, Theile D, Spalwisz A, Burhenne J,
Riedel KD and Haefeli WE: Influence of sildenafil and tadalafil on
the enzyme- and transporter-inducing effects of bosentan and
ambrisentan in LS180 cells. Biochem Pharmacol. 85:265–273. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gupta A, Mugundu GM, Desai PB, Thummel KE
and Unadkat JD: Intestinal human colon adenocarcinoma cell line
LS180 is an excellent model to study pregnane X receptor; but not
constitutive androstane receptor; mediated CYP3A4 and multidrug
resistance transporter 1 induction: Studies with anti-human
immunodeficiency virus protease inhibitors. Drug Metab Dispos.
36:1172–1180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Harper PA, Prokipcak RD, Bush LE, Golas CL
and Okey AB: Detection and characterization of the Ah receptor for
2;3;7;8-tetrachlorodibenzo-p-dioxin in the human colon
adenocarcinoma cell line LS180. Arch Biochem Biophys. 290:27–36.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
König J, Cui Y, Nies AT and Keppler D:
Localization and genomic organization of a new hepatocellular
organic anion transporting polypeptide. J Biol Chem.
275:23161–23168. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
König J, Cui Y, Nies AT and Keppler D: A
novel human organic anion transporting polypeptide localized to the
basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver
Physiol. 278:G156–G164. 2000.PubMed/NCBI
|
|
27
|
Pavek P, Merino G, Wagenaar E, Bolscher E,
Novotna M, Jonker JW and Schinkel AH: Human breast cancer
resistance protein: Interactions with steroid drugs, hormones, the
dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine,
and transport of cimetidine. J Pharmacol Exp Ther. 312:144–152.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boesch D, Gavériaux C, Jachez B,
Pourtier-Manzanedo A, Bollinger P and Loor F: In vivo circumvention
of P-glycoprotein-mediated multidrug resistance of tumor cells with
SDZ PSC 833. Cancer Res. 51:4226–4233. 1991.PubMed/NCBI
|
|
29
|
Peters T, Lindenmaier H, Haefeli WE and
Weiss J: Interaction of the mitotic kinesin Eg5 inhibitor monastrol
with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol.
372:291–299. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vandesompele J, De Preter K, Pattyn F,
Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate
normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol.
3(RESEARCH0034)2002.PubMed/NCBI
|
|
31
|
Fröhlich M, Albermann N, Sauer A,
Walter-Sack I, Haefeli WE and Weiss J: In vitro and ex vivo
evidence for modulation of P-glycoprotein activity by progestins.
Biochem Pharmacol. 68:2409–2416. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weiss J, Rose J, Storch CH,
Ketabi-Kiyanvash N, Sauer A, Haefeli WE and Efferth T: Modulation
of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob
Chemother. 59:238–245. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moreau P, Richardson PG, Cavo M, Orlowski
RZ, San Miguel JF, Palumbo A and Harousseau JL: Proteasome
inhibitors in multiple myeloma: 10 years later. Blood. 120:947–959.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Geick A, Eichelbaum M and Burk O: Nuclear
receptor response elements mediate induction of intestinal MDR1 by
rifampin. J Biol Chem. 276:14581–14587. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oerlemans R, Franke NE, Assaraf YG, Cloos
J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova
K, Lemos C, et al: Molecular basis of bortezomib resistance:
Proteasome subunit beta5 (PSMB5) gene mutation and overexpression
of PSMB5 protein. Blood. 112:2489–2499. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee DM,
Kim KB and Lee W: Development of peptide-based reversing agents for
p-glycoprotein-mediated resistance to carfilzomib. Mol Pharm.
9:2197–2205. 2012.PubMed/NCBI
|
|
37
|
Blagosklonny MV: STI-571 must select for
drug-resistant cells but ‘no cell breathes fire out of its nostrils
like a dragon’. Leukemia. 16:570–572. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
De Souza R, Zahedi P, Badame RM, Allen C
and Piquette-Miller M: Chemotherapy dosing schedule influences drug
resistance development in ovarian cancer. Mol Cancer Ther.
10:1289–1299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu DK: The contribution of P-glycoprotein
to pharmacokinetic drug-drug interactions. J Clin Pharmacol.
39:1203–1211. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Moreau P, Karamanesht II, Domnikova N,
Kyselyova MY, Vilchevska KV, Doronin VA, Schmidt A, Hulin C, Leleu
X, Esseltine DL, et al: Pharmacokinetic, pharmacodynamic, and
covariate analysis of subcutaneous versus intravenous
administration of bortezomib in patients with relapsed multiple
myeloma. Clin Pharmacokinet. 51:823–829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Summary of product characteristics for
Ninlaro. https://www.accessdata.fda.gov/drugsatfda_docs/label/…/208462lbl.pdf
|
|
42
|
Summary of product characteristics for
Kyprolis. simpleec.europa.eu/health/documents/…register/…/anx_133351_en.pdf
|
|
43
|
Wang Z, Yang J, Kirk C, Fang Y, Alsina M,
Badros A, Papadopoulos K, Wong A, Woo T, Bomba D, et al: Clinical
pharmacokinetics, metabolism, and drug-drug interaction of
carfilzomib. Drug Metab Dispos. 41:230–237. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Richardson PG, Baz R, Wang M, Jakubowiak
AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, et al:
Phase 1 study of twice-weekly ixazomib, an oral proteasome
inhibitor, in relapsed/refractory multiple myeloma patients. Blood.
124:1038–1046. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Thompson JL: Carfilzomib: A
second-generation proteasome inhibitor for the treatment of
relapsed and refractory multiple myeloma. Ann Pharmacother.
47:56–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
